JP2022549276A5 - - Google Patents

Info

Publication number
JP2022549276A5
JP2022549276A5 JP2022518285A JP2022518285A JP2022549276A5 JP 2022549276 A5 JP2022549276 A5 JP 2022549276A5 JP 2022518285 A JP2022518285 A JP 2022518285A JP 2022518285 A JP2022518285 A JP 2022518285A JP 2022549276 A5 JP2022549276 A5 JP 2022549276A5
Authority
JP
Japan
Prior art keywords
seq
immunocytokine
constant domain
heavy chain
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022518285A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022549276A (ja
Filing date
Publication date
Priority claimed from RU2019129569A external-priority patent/RU2753282C2/ru
Application filed filed Critical
Publication of JP2022549276A publication Critical patent/JP2022549276A/ja
Publication of JP2022549276A5 publication Critical patent/JP2022549276A5/ja
Priority to JP2025118407A priority Critical patent/JP2025182218A/ja
Pending legal-status Critical Current

Links

JP2022518285A 2019-09-19 2020-09-20 Il-15/il-15raに基づくヘテロ二量体タンパク質複合体を含む、イムノサイトカイン Pending JP2022549276A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025118407A JP2025182218A (ja) 2019-09-19 2025-07-14 Il-15/il-15raに基づくヘテロ二量体タンパク質複合体を含む、イムノサイトカイン

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
RU2019129569 2019-09-19
RU2019129569A RU2753282C2 (ru) 2019-09-19 2019-09-19 ИММУНОЦИТОКИН, ВКЛЮЧАЮЩИЙ ГЕТЕРОДИМЕРНЫЙ БЕЛКОВЫЙ КОМПЛЕКС НА ОСНОВЕ IL-15/IL-15Rα, И ЕГО ПРИМЕНЕНИЕ
PCT/RU2020/050233 WO2021054867A1 (ru) 2019-09-19 2020-09-20 Иммуноцитокин, включающий гетеро димерный белковый комплекс на основе il-15 и il-15rα

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025118407A Division JP2025182218A (ja) 2019-09-19 2025-07-14 Il-15/il-15raに基づくヘテロ二量体タンパク質複合体を含む、イムノサイトカイン

Publications (2)

Publication Number Publication Date
JP2022549276A JP2022549276A (ja) 2022-11-24
JP2022549276A5 true JP2022549276A5 (cg-RX-API-DMAC7.html) 2023-09-28

Family

ID=74873995

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022518285A Pending JP2022549276A (ja) 2019-09-19 2020-09-20 Il-15/il-15raに基づくヘテロ二量体タンパク質複合体を含む、イムノサイトカイン
JP2025118407A Pending JP2025182218A (ja) 2019-09-19 2025-07-14 Il-15/il-15raに基づくヘテロ二量体タンパク質複合体を含む、イムノサイトカイン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025118407A Pending JP2025182218A (ja) 2019-09-19 2025-07-14 Il-15/il-15raに基づくヘテロ二量体タンパク質複合体を含む、イムノサイトカイン

Country Status (21)

Country Link
US (1) US20230011234A1 (cg-RX-API-DMAC7.html)
EP (1) EP4032539A4 (cg-RX-API-DMAC7.html)
JP (2) JP2022549276A (cg-RX-API-DMAC7.html)
KR (1) KR20220145323A (cg-RX-API-DMAC7.html)
CN (1) CN115297885A (cg-RX-API-DMAC7.html)
AR (1) AR120011A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020351560A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022005173A2 (cg-RX-API-DMAC7.html)
CA (1) CA3151780A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022003156A2 (cg-RX-API-DMAC7.html)
JO (1) JOP20220071A1 (cg-RX-API-DMAC7.html)
MA (1) MA56286B1 (cg-RX-API-DMAC7.html)
MX (1) MX2022003306A (cg-RX-API-DMAC7.html)
PE (1) PE20220603A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022550688A1 (cg-RX-API-DMAC7.html)
PY (1) PY2056649A (cg-RX-API-DMAC7.html)
RU (1) RU2753282C2 (cg-RX-API-DMAC7.html)
TW (1) TWI891660B (cg-RX-API-DMAC7.html)
UY (1) UY38889A (cg-RX-API-DMAC7.html)
WO (1) WO2021054867A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202203254B (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113286812B (zh) 2018-09-27 2025-05-30 西里欧发展公司 掩蔽型细胞因子多肽
EP4251187A4 (en) 2020-11-25 2025-09-10 Xilio Dev Inc TUMOR-SPECIFIC CLASSIBLE LINKERS
US20250082777A1 (en) 2022-01-10 2025-03-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
CN116178572B (zh) * 2022-02-28 2025-12-23 厦门柏慈生物科技有限公司 构建嵌合蛋白的嵌合区域、构建方法、嵌合蛋白及其应用
CN115141283A (zh) * 2022-03-10 2022-10-04 厦门柏慈生物科技有限公司 一种融合蛋白、制备方法及其应用
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
CN116854821A (zh) * 2022-08-15 2023-10-10 海徕科(北京)生物技术有限公司 IL-15突变体-Fc/IL-15Rα亚基-Fc异源二聚体及其用途
WO2025031274A1 (zh) * 2023-08-04 2025-02-13 深圳众格生物科技有限公司 Sushi结构域突变体、融合蛋白、药物组合物和用途
CN122295373A (zh) * 2023-12-28 2026-06-26 南通壹宸生物医药科技有限公司 融合抗体及其应用
WO2025151752A1 (en) 2024-01-10 2025-07-17 Xilio Development, Inc. Masked il-2 cytokines and methods of use thereof
WO2026037415A1 (zh) * 2024-08-16 2026-02-19 北京清辉联诺生物科技有限责任公司 一种IL15/IL15Rα复合物及其在细胞疗法领域的应用
WO2026161860A1 (en) * 2025-01-27 2026-07-30 Kadmon Corporation, Llc Dosing of immunocytokines for cancer treatment

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
GB2183662B (en) 1985-04-01 1989-01-25 Celltech Ltd Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
DK0935607T3 (da) * 1996-08-16 2004-12-06 Harvard College Oplöselige monovalente og multivalente MHC klasse II-fusionsproteiner samt anvendelser deraf
BR9908082A (pt) * 1998-02-19 2000-10-31 Harvard College Proteìna de fusão do complexo de histocompatibilidade principal classe ii, conjugado dos domìnios de ligação do complexo de histocompatibilidade principal multimérico, processos para detectar células t tendo uma especificidade do complexo definido de mhc / peptìdeo, para conferir a um indivìduo imunidade adotiva a um complexo definido de mhc / peptìdeo, para estimular ou ativar as células t reativas a um complexo definido de mhc / peptìdeo, para seletivamente matar células t reativas a um complexo definido de mhc / peptìdeo, para tolerizar um indivìduo humano a um complexo definido de mhc / peptìdeo, e, ácido nucleico isolado
ES2387394T3 (es) * 1999-12-23 2012-09-21 Zymogenetics, Inc. Procedimiento de tratamiento de la inflamación
EP1777294A1 (en) 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
EP2388266B1 (en) * 2007-05-11 2014-04-23 Altor BioScience Corporation Fusion molecules and IL-15 variants
KR20120107122A (ko) * 2009-12-22 2012-09-28 노파르티스 아게 치료법에서 사용하기 위한 4가 cd47―항체 불변 영역 융합 단백질
JP6251570B2 (ja) * 2010-09-21 2017-12-20 アルター・バイオサイエンス・コーポレーション 多量体il−15可溶性融合分子並びにその製造及び使用方法
EP2537933A1 (en) * 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
CA2904805A1 (en) * 2013-04-29 2014-11-06 F. Hoffmann-La Roche Ag Fc-receptor binding modified asymmetric antibodies and methods of use
SI3030575T1 (sl) 2013-08-08 2018-11-30 Cytune Pharma Modulokini na osnovi IL-15 in IL-15R-alfa sushi domene
EP3093295B1 (en) * 2014-01-08 2020-05-27 Shanghai Hengrui Pharmaceutical Co., Ltd. Il-15 heterogeneous dimer protein and uses thereof
CA2953816C (en) * 2014-06-30 2022-03-15 Altor Bioscience Corporation Il-15-based molecules and methods of use thereof
US10905743B2 (en) 2014-12-19 2021-02-02 Jiangsu Hengrui Medicine Co., Ltd. Interleukin 15 protein complex
RU2656181C1 (ru) * 2016-07-13 2018-05-31 Закрытое Акционерное Общество "Биокад" Анти-pd-1-антитела, способ их получения и способ применения
MX2019004327A (es) 2016-10-14 2019-10-14 Xencor Inc Proteinas de fusion heterodimericas biespecificas que contienen proteinas de fusion fc il-15/il-15ra y fragmentos de anticuerpo pd-1.
MX2019004681A (es) * 2016-10-21 2019-10-07 Altor Bioscience Corp Moleculas basadas en il-15 multimericas.
KR102625293B1 (ko) * 2017-03-06 2024-01-15 알토 바이오사이언스 엘엘씨 Il-12 및 il-18로의 il-15-기반 융합
RU2665790C1 (ru) 2017-04-17 2018-09-04 Закрытое Акционерное Общество "Биокад" Моноклональное антитело к pd-l1
AU2018291497A1 (en) * 2017-06-30 2020-01-16 Xencor, Inc. Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains
US20200306301A1 (en) * 2017-07-03 2020-10-01 Torque Therapeutics, Inc. Polynucleotides Encoding Immunostimulatory Fusion Molecules and Uses Thereof

Similar Documents

Publication Publication Date Title
RU2019129569A (ru) ИММУНОЦИТОКИН, ВКЛЮЧАЮЩИЙ ГЕТЕРОДИМЕРНЫЙ БЕЛКОВЫЙ КОМПЛЕКС НА ОСНОВЕ IL-15/IL-15Rα, И ЕГО ПРИМЕНЕНИЕ
JP7464764B2 (ja) 抗ror1抗体とその作製及び使用方法
JP7685095B2 (ja) 多重特異性抗体とその作製及び使用方法
JP7356970B2 (ja) 多重特異性抗体とその作製及び使用方法
May et al. Advances in bispecific biotherapeutics for the treatment of cancer
JP2021525087A5 (cg-RX-API-DMAC7.html)
JP2023526774A5 (cg-RX-API-DMAC7.html)
JP2022521937A5 (cg-RX-API-DMAC7.html)
US20250270338A1 (en) Antibodies for t-cell activation
CN116948035A (zh) 多特异性抗体及其制备和使用方法
CN111094339B (zh) 抗pd-1抗体和抗lag-3抗体联合在制备治疗肿瘤的药物中的用途
JP2024504372A5 (cg-RX-API-DMAC7.html)
JP2022532991A5 (cg-RX-API-DMAC7.html)
CN112969718A (zh) Il-15蛋白复合物联合pd-l1抗体用于治疗肿瘤疾病的用途
JP2024527576A5 (cg-RX-API-DMAC7.html)
CN117679505A (zh) 药物组合及用途
US6007807A (en) Induction of tumour immunity by injection of hybrid cells
JPH05506037A (ja) インターロイキン2レセプターに対するモノクローナル抗体
Wang et al. The development of a next generation NK cell engager platform by integrating a potency-reduced IL-15 variant to enhance antitumor activity
De Jonge et al. Bispecific antibody treatment of murine B cell lymphoma
RU2020140807A (ru) Иммуноцитокин для активации IL-10Rα рецептора человека и его применение
EP4696715A1 (en) Medical use of anti-ctla4 and anti-pd-1 bispecific antibody
CA3304076A1 (en) Bispecific antibodies that bind cd3 and the ganglioside ngcgm3
NZ763865B2 (en) Antibodies specific to cd47 and pd-l1
Huang Engineered bispecific antibodies as cancer therapy